As President Donald Trump enters the first 100 days of his second term, he is once again making his stance on the oil and gas ...

Dozens of Texas superintendents met with lawmakers this month in Austin to back a bill some believe could curb violence ...

If it wasn't obvious before, Latigo Biotherapeutics is all in on its non-opioid pain treatment pipeline and that is highlighted further by the company's $150 million Series B capital raise. Announced ...

Big raises slowed for the second week in a row. Only a handful of rounds hit nine digits this week, although a large ...

The Food and Drug Administration has granted Fast Track designation to LTG-001 for the treatment of acute pain.

Latigo Biotherapeutics, Vivace Therapeutics, and Vori Health each announced the recent successful closing of their respective ...

A Texas state trooper accused of wrongfully killing a man in Converse after a pursuit exercised his right to remain silent ...

California-based Latigo Biotherapeutics, a biotech developing non-opioid pain treatments, has closed $150 million in a Series B financing.

Latigo Biotherapeutics has secured $150m in a Series B financing round, which will be used to further the development of its Na v 1.8 inhibitors, which are being developed as non-opioid treatments for ...

From STAT’s Andrew Joseph: AstraZeneca said this morning it was buying the Belgian cell therapy company EsoBiotec for $425 million upfront, building out another cancer-targeting approach.

The round, which included more than a dozen investment firms, should give the startup enough cash to get late-stage data for ...

Latigo Biotherapeutics has tapped into investor interest in pain relief medicines with new, non-opioid mechanisms of action, ...